Clinical Trial Update: An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

View source ↗

Summary

This notice indicates that Janssen-Cilag's expanded access program using decitabine for myelodysplastic syndromes is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Dacogen (decitabine)

Snippet

Sponsor: Janssen-Cilag Farmaceutica Ltda. | Conditions: Myelodysplastic Syndromes | Status: NO_LONGER_AVAILABLE